Summit Therapeutics plc : Holding(s) in Company

Summit Therapeutics plc
("Summit" or the "Company")

HOLDINGS IN COMPANY

Oxford, UK, 17 March 2015 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, has become aware that the persons named below have become interested in 3,856,105 ordinary shares of 1p each ("Ordinary Shares") representing 6.6% of the Company's ordinary share capital. The interests are held in the form of American Depositary Shares each of which represents five Ordinary Shares ("ADSs").

The persons interested are (i) Point72 Asset Management, L.P. ("Point72 Asset Management") with respect to ADSs held by certain investment funds it manages; (ii) Point72 Capital Advisors, Inc. ("Point72 Capital Advisors") with respect to ADSs held by certain investment funds managed by Point72 Asset Management; and (iii) Steven A. Cohen ("Mr Cohen") with respect to ADSs beneficially owned by Point72 Asset Management and Point72 Capital Advisors.

Point72 Asset Management, Point72 Capital Advisors and Mr Cohen have stated that they own directly no ADSs nor Ordinary Shares. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by certain investment funds it manages. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Mr Cohen controls Point72 Capital Advisors Inc. Each of Point72 Asset Management, Point72 Capital Advisors Inc. and Mr Cohen has disclaimed beneficial ownership of any of the securities covered by this statement.

The information in this announcement is taken from a public filing made with the US Securities and Exchange Commission by Point72 Asset Management, Point72 Capital Advisors and Mr Cohen and has not been independently verified by the Company.

- END -

Notes to Editors

About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy and the infectious disease C. difficile infection.


For more information, please contact: